NCT04841499View on ClinicalTrials.gov

Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 5, 2021

Primary Completion Date

July 15, 2021

Study Completion Date

July 15, 2021

Conditions
Menopause
Interventions
DRUG

BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)

take 2 capsules orally each day for 7 days

Trial Locations (1)

36604

University of South Alabama, Mobile

All Listed Sponsors
collaborator

Elysium Health, Inc.

UNKNOWN

lead

University of South Alabama

OTHER

NCT04841499 - Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause | Biotech Hunter | Biotech Hunter